Artal Group S.A. — 13F Holdings & Portfolio
CIK 1053906 · latest 13F-HR filed 2026-05-14
Artal Group S.A. manages $1.01B in 13F-reported U.S. long-equity assets across 2 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are CAVA (76.11%), LXRX (23.89%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 0, added to 2, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.01B
Long-equity book
2
Distinct positions
2026-03-31
Filed 2026-05-14
+0 / −0 / ↑2 / ↓0
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Cava Group Inc$211.2M +37.8%
- Lexicon Pharmaceuticals Inc$84.8M +54.1%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $1.01B | 2 | 0001053906-26-000006 |
| 2025-12-31 | 2026-02-12 | $714.6M | 2 | 0001053906-26-000003 |
| 2025-09-30 | 2025-11-12 | $758.2M | 2 | 0001053906-25-000012 |